The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SOUNDTRACK-E: A phase 1/2, open-label, multicenter study to evaluate the safety and efficacy of AZD0486 monotherapy or combination therapy in patients with mature B-cell malignancies.
 
Toby Eyre
Honoraria - Abbvie; AstraZeneca/MedImmune; Autolus Therapeutics; Galapagos NV; Gilead Sciences; Incyte; Janssen Oncology; Loxo/Lilly; Roche; Secura Bio
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; Autolus Therapeutics; BeiGene; Galapagos NV; Incyte; Kite/Gilead; Lilly; Loxo; Roche; Secura Bio
Research Funding - AstraZeneca/MedImmune; BeiGene
Travel, Accommodations, Expenses - Roche
 
Joanna Rhodes
Honoraria - Aptitude Health; Curio Science; Dava Oncology; MJH Life Sciences
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene/Juno; Epizyme; Epizyme; Genentech; Genmab; Janssen; Johnson and Johnson; Loxo/Lilly; Morphosys; Pfizer; Pharmacyclics; SeaGen; TG Therapeutics; Verastem
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); BeiGene (Inst); Epizyme (Inst); Johnson & Johnson/Janssen (Inst); Loxo/Lilly (Inst); Merck (Inst); Oncternal Therapeutics (Inst); Pharmacyclics (Inst); VelosBio (Inst)
Travel, Accommodations, Expenses - Curio Science; DAVA Pharmaceuticals; Loxo; Merck
 
Chan Cheah
Honoraria - AstraZeneca (Inst); BeiGene (Inst); crispr therapeutics; Dizal Pharma (Inst); Gilead Sciences; Janssen-Cilag (Inst); Loxo/Lilly; Menarini (Inst); Novartis; Roche/Genentech (Inst); SOBI; TG Therapeutics
Consulting or Advisory Role - AstraZeneca; BeiGene (Inst); Dizal Pharma (Inst); Gilead Sciences; Janssen-Cilag; Kite, a Gilead company (Inst); Loxo/Lilly; Menarini (Inst); Roche/Genentech (Inst)
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - BeiGene; Lilly; Roche
 
Steven Le Gouill
No Relationships to Disclose
 
Won Kim
Research Funding - BeiGene; BeiGene; Boryung; Sanofi
 
Shenmiao Yang
No Relationships to Disclose
 
Martin Hutchings
Consulting or Advisory Role - Abbvie; AstraZeneca; Genmab; Johnson & Johnson/Janssen; Roche; Takeda
Research Funding - Abbvie (Inst); Arvinas (Inst); AstraZeneca (Inst); Celgene (Inst); Genmab (Inst); Johnson & Johnson/Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
 
Matthew Stankowicz
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Robin Lesley
Employment - AstraZeneca
Stock and Other Ownership Interests - Amgen; AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Xu (Sue) Zhu
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca; Novartis
 
Mihail Obrocea
Employment - AstraZeneca
Leadership - MAIA Biotechnology
Stock and Other Ownership Interests - MAIA Biotechnology
 
Yuyin Liu
Employment - AstraZeneca
 
Firasath Ali Syed
Employment - AstraZeneca
 
Nikolaus Jahn
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Mak Ahmed
Employment - AstraZeneca
 
Matthew Davids
Honoraria - Aptitude Health; Bio Ascend; Curio Science; PlatformQ Health; Plexus; Research to Practice
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene; Bristol-Myers Squibb; Galapagos NV; Genentech; Genmab; Janssen; Lilly; MEI Pharma; Merck; Nuvalent, Inc.; Secura Bio; Takeda; TG Therapeutics
Research Funding - Ascentage Pharma (Inst); MEI Pharma (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Up-to-date royalties